Xenoport (XNPT) is a biopharmaceutical that develops and markets internally discovered candidates with a focus on neurological disorders. Currently the company has a single commercial stage product in the US. Horizant (gabapentin enacarbil) is approved for the treatment of restless legs syndrome (RLS), and postherpetic neuralgia (PHN).
Xenoport shares have been depressed lately, steadily sinking from a high of more than $12.50 in October of 2012, to a recent price of about $4.80. Horizant sales are significant, but hardly enough to bring the company to profitability. In May 2013, failure of its lead candidate to reach its primary endpoint in a Phase 3 trial didn't help any.
Despite the clinical setback, there is a bright glimmer of hope...
Only subscribers can access this article, which is part of the PRO research library covering 3,575 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: